

# Questions and Answers

## Rights Issue 2025

### Record Date and Subscription Period

**Q: What is the record date for participation in the rights issue?**

**A:** The record date for participation in the rights issue is 14 October 2025.

**Q: When can I subscribe for the unit rights I have been allocated?**

**A:** The subscription period runs from 16 October to 30 October 2025. Please follow the instructions provided by your bank or nominee to subscribe for your unit rights.

Please note that certain banks and nominees may close the subscription process early and sell your unit rights on the market before the end of the subscription period. Therefore, it is recommended to submit your subscription request as soon as the subscription period has commenced.

---

### Terms and Definitions

**Q: What is a unit right (UR) and a paid subscribed unit (BTU)?**

**A:** A unit right (UR) is a security that entitles the holder to subscribe for units in the rights issue. Existing shareholders receive unit rights based on the number of shares held after the market closes on 14 October 2025 (the record date). Unit rights are expected to have a market value and may be sold if the holder does not wish to exercise them for subscription.

A paid subscribed unit (BTU) is a unit that has been subscribed and paid for. A BTU has a market value as it will later be converted into shares and warrants of series TO7. In this case, each unit consists of eighteen (18) new shares and twelve (12) warrants of series TO7.

**Q: What is a warrant?**

**A:** A warrant is a financial instrument that gives the holder the right, but not the obligation, to purchase new shares in a company at a predetermined price (the subscription price) during a specified period.

---

### Practical Information on Subscribing for Units

**Q: How do I, as a shareholder, subscribe?**

**A:** First, determine whether your holding in Lumito is nominee-registered (for example via Nordnet, Avanza, or your regular bank) or directly registered (VP account).

If your holding is nominee-registered, follow the instructions from your nominee or bank. You will usually receive a notification of a corporate action, asking for your response.

If your holding is directly registered, you will receive a pre-printed subscription form with an attached payment slip from Euroclear.

**Example:**

A shareholder holding 500 shares in Lumito will receive 500 unit rights, which will appear in the shareholder's account on the first day of the subscription period, 16 October 2025. To maintain their ownership proportion in Lumito AB, all unit rights must be used for subscription.

Two (2) unit rights are required to subscribe for one (1) unit. The shareholder therefore uses 500 unit rights to subscribe for 250 BTUs, which will later be converted into shares and warrants. The subscription price is SEK 0.45 per unit, resulting in a total cost of SEK 112.50. The shareholder's BTUs will be converted into 4,500 new shares and 3,000 warrants of series TO7.

**Q: I am not currently a shareholder but would like to participate in the issue. How do I do that?**

**A:** You can either purchase unit rights (LUMITO UR) on the market to ensure allocation of BTUs, or subscribe without preferential rights (i.e., without unit rights) by registering your interest through your bank or nominee, or directly via Mangold's website: <https://emission.mangold.se/>.

---

**Proceeds and Use of Funds**

**Q: What will the proceeds from the rights issue be used for?**

**A:** The proceeds will be raised in two stages. Initially, Lumito may receive up to approximately SEK 60 million from the rights issue before costs. In June 2026, the company may receive an additional SEK 49 million through the exercise of TO6 warrants.

It is important to note that a underwriting agreements of SEK 35 million has been secured in advance, enabling continued operations until funds from the warrant exercise are received, even if the issue is not fully subscribed.

Proceeds from the rights issue will be used to accelerate commercialisation, with an initial focus on Europe over the next 6–12 months; to launch additional reagent kits; to enhance functionality within quantification, user support and AI-based analysis; and to prepare for a clinical product.

Proceeds from TO6 warrant exercises will support geographical expansion outside Europe through partnerships and distribution agreements, the development of additional reagent kits, and the strengthening of expertise and resources related to clinical market product specifications and diagnostics.

Funds from the rights issue will also be used to strengthen the balance sheet by repaying part of the loan from Fenja Capital A/S and a bridge loan. Proceeds from the warrants will be used to repay the remaining loan to Fenja Capital A/S.

**Q: Is the issue underwritten in any way?**

**A:** Yes. The issue is secured to approximately 60 per cent through subscription commitments and underwriting commitments amounting to around SEK 35 million from external investors. This means that Lumito will receive at least that amount (before costs) even if the issue is not fully subscribed. The underwritten level ensures continued operations through to the completion of the warrant exercise.

**Q: Why did the Board decide on such a large issue? Wouldn't it have been better to split it into several tranches?**

**A:** The size of the issue is based on an assessment of the capital required to advance our projects and to continue early commercial activities aimed at testing and validating our business model through pilot projects and customer feedback. This will place us in a strong, long-term position for market expansion and geographical growth through partnerships and distribution agreements.

Another important aspect is our ambition to ensure financial stability, enabling the development of additional reagent kits and further strengthening our expertise and resources for defining product specifications for the clinically regulated market. A larger, secured issue provides the best possible conditions for focusing fully on building long-term value in the company.

---

## **Customer Dialogue and Commercial Progress**

**Q: What progress has been made commercially? Are there concrete customer discussions?**

**A:** Yes. Lumito is already collaborating with two contract research organisations (CROs) that plan to offer testing on SCIZYS to their pharmaceutical development clients. The company is also in discussions with additional CROs and research institutions that see value in the technology for their operations. These partnerships are an important part of Lumito's commercialisation strategy and further confirm the practical applications of Scizys.

---

## **Other Questions**

**Q: Are you planning a reverse share split (share consolidation)?**

**A:** A share consolidation (reverse split) may be considered at a later stage if deemed to be in the best interests of the company and its shareholders.

**Q: How can shareholders support the company moving forward?**

**A:** The most important support our shareholders can provide at this stage is continued

patience and confidence in our long-term plan. We are working with clear focus to build a stable, sustainable, and value-creating company.

We encourage shareholders to follow our updates via the website, press releases, and reports, and to participate in general meetings and other shareholder dialogues. The engagement of our shareholders is highly appreciated and contributes to strengthening the company's position.